This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Dermatology				
Dermatitis	Cysteinyl leukotriene receptor 2 (CysLTR2); leukotriene C4 synthase (LTC4S)	Mouse studies suggest inhibiting leukotriene C4 signaling through LTC4S and CysLT2 could help treat atopic dermatitis. In a mouse model of atopic dermatitis, <i>Ltc4s</i> or <i>Cyslt2</i> knockout decreased allergen-induced skin thickening and collagen deposition compared with wild-type expression. Next steps could include screening for small molecule inhibitors of LTC4S and CysLT2. SciBX 5(13); doi:10.1038/scibx.2012.337 Published online March 29, 2012	Patent and licensing status unavailable	Oyoshi, M.K. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online March 13, 2012; doi:10.1073/pnas.1203127109 Contact: Raif S. Geha, Harvard Medical School, Boston, Mass. e-mail: raif.geha@childrens.harvard.edu Contact: K. Frank Austen, same affiliation as above e-mail: fausten@rics.bwh.harvard.edu